Evaluation of gut microbiota composition in elite controllers and antiretroviral-treated people with HIV after aspirin versus atorvastatin administration.

Authors

Mia Marotti, Brian P Epling, Angelina Angelova, Elisha Segrist, Elizabeth Laidlaw, April Poole, Maura Manion, Stephen Migueles, Jason Baker, Irini Sereti

Published in

The Journal of infectious diseases. Oct 09, 2026. Epub Oct 09, 2026.

Abstract

Gut dysbiosis is associated with chronic immune activation in people with HIV (PWH), but is not well-characterized in elite controllers (ECs) or PWH receiving aspirin or statins. We analyzed gut microbiota among 22 virally-suppressed PWH and 12 ECs before and 9-months after randomization to aspirin or atorvastatin. There were no differences in microbiota between PWH and EC at baseline. There was a significant change in beta diversity after aspirin administration, but no difference in microbiota after atorvastatin. These findings suggest that ECs have gut microbiota resembling virally-suppressed PWH, and aspirin but not atorvastatin may impact gut microbiota diversity in PWH.

PMID:
42853985
Bibliographic data and abstract were imported from PubMed on 10 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.